PT  - JOURNAL ARTICLE
AU  - Peter C. Albertsen
TI  - Prostate-specific antigen: How to advise patients as the screening debate continues
DP  - 2005 Jun 01
TA  - Cleveland Clinic Journal of Medicine
PG  - 521--527
VI  - 72
IP  - 6
4099  - http://www.ccjm.org/content/72/6/521.short
4100  - http://www.ccjm.org/content/72/6/521.full
SO  - Cleve Clin J Med2005 Jun 01; 72
AB  - There is still no consensus on whether prostate-specific antigen (PSA) measurement should be used as a screening test for prostate cancer, but patients have the right to be informed about its risks and possible benefits. PSA testing is more likely to be beneficial in relatively young men and men at higher risk (ie, African Americans and men with a family history of prostate cancer). A possible schedule is to test at age 40, age 45, and every 2 to 3 years from age 50 until about age 75.